Research Report
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2014; 20(15): 4362-4369
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4362
Table 2 Demographic and baseline characteristics of the study population
CharacteristicsTotal patients n = 268Esomeprazole therapy n = 134Lansoprazole therapy n = 134
Age (yr) (mean ± SD) range61 ± 14 23-9261 ± 13 25-8461 ± 14 23-92
Sex, male, %186, 69%92, 69%94, 70%
BMI (mean ± SD)22.9 ± 3.522.7 ± 3.523.0 ± 3.5
Alcohol1, n, (%)119, 44%54, 42%65, 49%
Smoking (%)75, 28%37, 28%38, 28%
Underlying diseases
Hypertension, n, %69, 26%35, 26%34, 25%
Diabetes mellitus, n, %35, 13%18, 13%17, 13%
Lipid disorder, n, %31, 12%12, 9%19, 14%
Chronic lung disease, n, %7, 3%4, 3%3, 2%
Disease for H. pylori eradication
Gastric ulcer, n, %163, 61%82, 61%81, 61%
Duodenal ulcer, n, %59, 22%29, 22%30, 22%
Gastroduodenal ulcer, n, %7, 3%5, 4%2, 1.5%
Gastric MALT lymphoma, n, %2, 0.7%0, 0%2, 1.5%
ITP, n, %1, 0.4%1, 0.8%0, 0%
EGC after endoscopic therapy, n, %36, 13%17, 13%19, 14%
Therapy and test for H. pylori eradication
Clarithromycin 400 mg/800 mg per day28/23312/11816/115
Urea breath test/stool antigen test/others230/17/4113/8/3117/9/1
Compliance2
Good, n, %226 (84%)110 (82%)116 (87%)

  • Citation: Nishida T, Tsujii M, Tanimura H, Tsutsui S, Tsuji S, Takeda A, Inoue A, Fukui H, Yoshio T, Kishida O, Ogawa H, Oshita M, Kobayashi I, Zushi S, Ichiba M, Uenoyama N, Yasunaga Y, Ishihara R, Yura M, Komori M, Egawa S, Iijima H, Takehara T. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. World J Gastroenterol 2014; 20(15): 4362-4369
  • URL: https://www.wjgnet.com/1007-9327/full/v20/i15/4362.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v20.i15.4362